Uehara Y - Search Results

1

Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.

Uehara Y, Watanabe K, Hakozaki T, Yomota M, Hosomi Y. Uehara Y, et al. Thorac Cancer. 2022 Jun;13(11):1703-1711. doi: 10.1111/1759-7714.14448. Epub 2022 May 2. Thorac Cancer. 2022. PMID: 35491960 Free PMC article.

2

Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy.

Uehara Y, Hakozaki T, Kitadai R, Narita K, Watanabe K, Hashimoto K, Kawai S, Yomota M, Hosomi Y. Uehara Y, et al. Transl Lung Cancer Res. 2022 Feb;11(2):135-149. doi: 10.21037/tlcr-21-815. Transl Lung Cancer Res. 2022. PMID: 35280320 Free PMC article.

3

Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer.

Uehara Y, Hakozaki T. Uehara Y, et al. Transl Lung Cancer Res. 2023 Jan 31;12(1):6-10. doi: 10.21037/tlcr-22-872. Epub 2022 Dec 26. Transl Lung Cancer Res. 2023. PMID: 36762059 Free PMC article. No abstract available.

4

Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report.

Kobayashi T, Uehara Y, Watanabe K, Hishima T, Hosomi Y. Kobayashi T, et al. Among authors: uehara y. JTO Clin Res Rep. 2023 Jun 15;4(7):100538. doi: 10.1016/j.jtocrr.2023.100538. eCollection 2023 Jul. JTO Clin Res Rep. 2023. PMID: 37456922 Free PMC article.

5

Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy.

Terashima Y, Hakozaki T, Uehara Y, Miyanaga A, Kasahara K, Seike M, Hosomi Y. Terashima Y, et al. Among authors: uehara y. Int J Clin Oncol. 2024 Feb;29(2):115-123. doi: 10.1007/s10147-023-02436-5. Epub 2023 Nov 30. Int J Clin Oncol. 2024. PMID: 38032455

6

Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC.

Hirata T, Uehara Y, Hakozaki T, Kobayashi T, Terashima Y, Watanabe K, Yomota M, Hosomi Y. Hirata T, et al. Among authors: uehara y. JTO Clin Res Rep. 2024 Mar 5;5(4):100659. doi: 10.1016/j.jtocrr.2024.100659. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38596201 Free PMC article.

7

Shen X, Xie J, Liu S, Cai Y, Yuan S, Uehara Y, Zhu D, Zheng M. Shen X, et al. Among authors: uehara y. J Thorac Dis. 2024 Aug 31;16(8):5361-5378. doi: 10.21037/jtd-24-1123. Epub 2024 Aug 28. J Thorac Dis. 2024. PMID: 39268091 Free PMC article.

8

Targeting the FGF/FGFR axis and its co-alteration allies.

Uehara Y, Ikeda S, Kim KH, Lim HJ, Adashek JJ, Persha HE, Okamura R, Lee S, Sicklick JK, Kato S, Kurzrock R. Uehara Y, et al. ESMO Open. 2022 Dec;7(6):100647. doi: 10.1016/j.esmoop.2022.100647. Epub 2022 Nov 29. ESMO Open. 2022. PMID: 36455506 Free PMC article.

9

Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression.

Uehara Y. Uehara Y. Transl Lung Cancer Res. 2023 Mar 31;12(3):401-404. doi: 10.21037/tlcr-23-103. Epub 2023 Mar 24. Transl Lung Cancer Res. 2023. PMID: 37057125 Free PMC article. No abstract available.

10

Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital.

Uehara Y, Koyama T, Katsuya Y, Sato J, Sudo K, Kondo S, Yoshida T, Shoji H, Shimoi T, Yonemori K, Yamamoto N. Uehara Y, et al. JAMA Netw Open. 2023 Sep 5;6(9):e2333188. doi: 10.1001/jamanetworkopen.2023.33188. JAMA Netw Open. 2023. PMID: 37713200 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,091 results

Search Page

Filters